Grundlæggende statistik
| CIK | 1558569 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to iSpecimen Inc.
SEC Filings (Chronological Order)
Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.
| June 4, 2026 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-3 iSpecimen Inc. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Common Stock, $0.0001 |
|
| June 4, 2026 |
As filed with the Securities and Exchange Commission on June 4, 2026 As filed with the Securities and Exchange Commission on June 4, 2026 Registration No. |
|
| June 1, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 29, 2026 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of Incorporation) (Commission File Number |
|
| May 29, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 29, 2026 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of Incorporation) (Commission File Number |
|
| May 18, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2026 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-40501 iSpecimen Inc. ( |
|
| May 18, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2026 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Perio |
|
| May 18, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| May 13, 2026 |
Exhibit 10.3 PLACEMENT AGENCY AGREEMENT May 7, 2026 PERSONAL AND CONFIDENTIAL iSpecimen Inc. 8 Cabot Rd., Suite 1800 Woburn, MA 01801 Attention: Katharyn Field, Chief Executive Officer Dear Ms. Field: This agreement (the “Agreement”) constitutes the agreement between E.F. Hutton & Co. (the “Placement Agent”) on one hand, and iSpecimen Inc., a company incorporated under the laws of Delaware (the “C |
|
| May 13, 2026 |
Exhibit 4.1 iSPECIMEN INC. NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EF |
|
| May 13, 2026 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is entered into and made effective as of [], 2026, by and among iSpecimen Inc., a Delaware corporation (the “Company”), each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). RECITALS WHEREAS, subject to the |
|
| May 13, 2026 |
iSpecimen Inc. Announces Pricing of Approximately $2.5 Million Private Placement May 8, 2026 Exhibit 99.1 iSpecimen Inc. Announces Pricing of Approximately $2.5 Million Private Placement May 8, 2026 WOBURN, Mass., May 08, 2026 (GLOBE NEWSWIRE) - iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it has priced a p |
|
| May 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 8, 2026 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of Incorporation) (Commission File Number) |
|
| May 13, 2026 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of May 7, 2026 between iSpecimen Inc., a Delaware corporation (the “Company”), and each purchaser appearing on the signature page to the Purchase Agreement (as defined below) (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). WHEREAS, the Company and t |
|
| May 1, 2026 |
iSpecimen Announces 1-for-40 Reverse Stock Split Exhibit 99.1 iSpecimen Announces 1-for-40 Reverse Stock Split WOBURN, Mass., April 24, 2026 – iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today that it will effect a reverse stock split of its issued and outstanding shares of |
|
| May 1, 2026 |
Exhibit 3.2 CERTIFICATE OF VALIDATION OF iSPECIMEN INC. Pursuant to Section 204 of the General Corporation Law of the State of Delaware iSpecimen Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify as follows: 1. The name of the Corporation is iSpecimen Inc. The original certificate of incorporation of the Corporation was file |
|
| May 1, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 29, 2026 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of Incorporation) (Commission File Numb |
|
| May 1, 2026 |
FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION iSPECIMEN INC. April 29, 2026 Exhibit 3.1 FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF iSPECIMEN INC. April 29, 2026 iSpecimen Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY AS FOLLOWS: 1. The name of the Corporation is “iSpecimen Inc.” The original certificate of incorporation of the Corporation was filed with the Secretary of State of |
|
| April 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 10, 2026 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of Incorporation) (Commission File Numb |
|
| April 10, 2026 |
iSpecimen achieves 85% Reduction in Human Biospecimen Shipping Time Exhibit 99.1 FOR IMMEDIATE RELEASE iSpecimen achieves 85% Reduction in Human Biospecimen Shipping Time Woburn, MA — April 9, 2026 — iSpecimen, an online marketplace for human biospecimens, has implemented a streamlined shipping model that enables direct shipment of biospecimens from supplier sites to customers, both domestically and internationally. By reducing reliance on centralized hub processi |
|
| April 10, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 9, 2026 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of Incorporation) (Commission File Numbe |
|
| April 1, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-40501 iSpecimen Inc. (Exact |
|
| March 31, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2025 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-K ☐ Transition Report o |
|
| March 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 13, 2026 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of Incorporation) (Commission File Numb |
|
| March 3, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| February 23, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 17, 2026 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of Incorporation) (Commission File N |
|
| February 18, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 13, 2026 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of Incorporation) (Commission File N |
|
| February 6, 2026 |
Exhibit 99.1 iSpecimen Announces Milestone 2: System Integration and Marketplace Activation Complete Live Production Marketplace Now Available Woburn, MA - February 6, 2026: iSpecimen Inc. (NASDAQ: ISPC) today announced the successful completion of Milestone 2, System Integration and Marketplace Activation, marking a pivotal step in the SalesStack digital transformation journey. The milestone deli |
|
| February 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 6, 2026 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of Incorporation) (Commission File Nu |
|
| February 6, 2026 |
iSpecimen Achieves Rapid Procurement Milestone for Influenza Research Exhibit 99.2 iSpecimen Achieves Rapid Procurement Milestone for Influenza Research Lexington, MA — February 6, 2026 — iSpecimen Inc. (NASDAQ: ISPC), a leading provider of human biospecimens for research, is proud to announce recent milestones that demonstrate the strength, responsiveness, and reliability of its site network. Over the past several months, iSpecimen has been actively supporting cust |
|
| February 3, 2026 |
101,000,000 Shares of Common Stock PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-292804 101,000,000 Shares of Common Stock This prospectus relates to the offer and resale of up to an aggregate of 101,000,000 shares of common stock, par value $0.0001 per share (“Common Stock” or ‘common stock”), of iSpecimen Inc., held by selling stockholders, consisting of the following: (i) up to 101,000,000 shares of common sto |
|
| January 28, 2026 |
iSpecimen Inc. 8 Cabot Road, Suite 1800 Woburn, WA 08101 iSpecimen Inc. 8 Cabot Road, Suite 1800 Woburn, WA 08101 January 28, 2026 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: iSpecimen Inc. Request for Acceleration Registration Statement on Form S-3 File No. 333-292804 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended (th |
|
| January 27, 2026 |
January 27, 2026 Katharyn Field Chief Executive Officer iSpecimen Inc. 8 Cabot Road, Suite 1800 Woburn, MA 01801 Re: iSpecimen Inc. Registration Statement on Form S-3 Filed January 20, 2026 File No. 333-292804 Dear Katharyn Field: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. W |
|
| January 27, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 23, 2026 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of Incorporation) (Commission File Nu |
|
| January 20, 2026 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-3 iSpecimen Inc. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Common Stock, $0.0001 |
|
| January 20, 2026 |
As filed with the Securities and Exchange Commission on January 16, 2026 As filed with the Securities and Exchange Commission on January 16, 2026 Registration No. |
|
| January 16, 2026 |
Exhibit 3.1 AMENDED CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF THE SERIES C CONVERTIBLE PREFERRED STOCK OF ISPECIMEN INC. pursuant to section 151(g) of the delaware General Corporation law RECITALS WHEREAS, iSpecimen Inc., a Delaware corporation (the “Corporation”), previously filed on December 30, 2025 a Certificate of Designations, Preferences and Rights of the Series C Convertible P |
|
| January 16, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 30, 2025 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of Incorporation |
|
| January 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| January 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 31, 2025 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of Incorporation) (Commission File N |
|
| January 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 31, 2025 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of Incorporation) (Commission File N |
|
| January 5, 2026 |
Exhibit 10.1 CONSULTING AGREEMENT IR Agency LLC (the “Consultant” or “IR Agency”) is pleased to provide certain consulting services to Ispecimen Inc. (“you,” “Client” or “Company”) as more fully described in this agreement (the “Agreement”). This Agreement sets forth the terms and conditions pursuant to which Company engages Consultant to provide such services. 1. Consulting Services. (a) Commenci |
|
| January 2, 2026 |
Exhibit 10.3 PLACEMENT AGENCY AGREEMENT December 30, 2025 PERSONAL AND CONFIDENTIAL iSpecimen Inc. 8 Cabot Rd., Suite 1800 Woburn, MA 01801 Attention: Katharyn Field, Chief Executive Officer Dear Ms. Field: This agreement (the “Agreement”) constitutes the agreement between E.F. Hutton & Co. (the “Placement Agent”) on one hand, and iSpecimen Inc., a company incorporated under the laws of Delaware ( |
|
| January 2, 2026 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is entered into and made effective as of December 30, 2025, by and among iSpecimen Inc., a Delaware corporation (the “Company”), each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). RECITALS WHEREAS, subje |
|
| January 2, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 30, 2025 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of Incorporation) (Commission File N |
|
| January 2, 2026 |
1,559,828 Shares of Common Stock PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-289725 1,559,828 Shares of Common Stock This prospectus relates to the offer and resale of up to an aggregate of 1,559,828 shares of common stock, par value $0.0001 per share, of iSpecimen Inc., held by selling stockholders, consisting of the following: (i) 267,379 shares of common stock (the “Shares”) and (ii) 1,292,449 shares of co |
|
| January 2, 2026 |
Exhibit 3.1 CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF THE SERIES C CONVERTIBLE PREFERRED STOCK OF ISPECIMEN INC. pursuant to section 151(g) of the delaware General Corporation law The undersigned, Katharyn Field, the Chief Executive Officer of iSpecimen Inc. (the “Corporation”), a Delaware corporation, hereby does certify: That pursuant to the authority expressly conferred upon the Bo |
|
| January 2, 2026 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of December 30, 2025 between iSpecimen Inc., a Delaware corporation (the “Company”), and each purchaser appearing on the signature page to the Purchase Agreement (as defined below) (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). WHEREAS, the Company |
|
| December 19, 2025 |
As filed with the Securities and Exchange Commission on December 19, 2025 As filed with the Securities and Exchange Commission on December 19, 2025 Registration No. |
|
| December 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 28, 2025 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of Incorporation) (Commission File N |
|
| November 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 19, 2025 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of Incorporation) (Commission File N |
|
| November 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive |
|
| November 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-40501 iSpecimen In |
|
| November 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: September 30, 2025 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition P |
|
| November 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| November 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 7, 2025 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of Incorporation) (Commission File Nu |
|
| November 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 30, 2025 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| October 23, 2025 |
As filed with the Securities and Exchange Commission on October 23, 2025 As filed with the Securities and Exchange Commission on October 23, 2025 Registration No. |
|
| October 23, 2025 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-3 iSpecimen Inc. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Common Stock (1) 457(o |
|
| October 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive |
|
| October 6, 2025 |
As filed with the Securities and Exchange Commission on October 6, 2025 As filed with the Securities and Exchange Commission on October 6, 2025 Registration No. |
|
| October 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION (Amendment No. 2) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| September 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION (Amendment No. 1) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| September 8, 2025 |
As filed with the Securities and Exchange Commission on September 8, 2025 As filed with the Securities and Exchange Commission on September 8, 2025 Registration No. |
|
| September 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 4, 2025 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of Incorporation) (Commission File N |
|
| September 4, 2025 |
iSpecimen Approached by Crypto Currency Companies for $200 Million Treasury Discussions Exhibit 99.1 iSpecimen Approached by Crypto Currency Companies for $200 Million Treasury Discussions Woburn, MA – September 4, 2025 – iSpecimen Inc. (NASDAQ: ISPC), (the “Company”), a technology-enabled company modernizing the way human biospecimens are sourced for scientific research, today announced an update on its major strategic initiative aimed at integrating digital assets into its business |
|
| August 25, 2025 |
As filed with the Securities and Exchange Commission on August 25, 2025 As filed with the Securities and Exchange Commission on August 25, 2025 Registration No. |
|
| August 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 21, 2025 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of Incorporation) (Commission File Num |
|
| August 21, 2025 |
Exhibit 99.1 iSpecimen Announces Completion of Milestone 1 in Digital Transformation Journey with Salestack Platform Woburn, MA – August 21, 2025 – iSpecimen Inc. (NASDAQ: ISPC), an online marketplace for human biospecimens, today announced the successful completion of Milestone 1 in its digital transformation program powered by Salestack Solutions. This critical achievement marks the installation |
|
| August 20, 2025 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-1 iSpecimen Inc. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Common Stock, $0.0001 |
|
| August 20, 2025 |
As filed with the Securities and Exchange Commission on August 20, 2025 As filed with the Securities and Exchange Commission on August 20, 2025 Registration No. |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-40501 iSpecimen Inc. (E |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 7, 2025 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of Incorporation) (Commission File Numb |
|
| August 7, 2025 |
iSpecimen to Establish $200M Corporate Treasury Built Around Solana Cryptocurrency with BlockArrow Exhibit 99.1 iSpecimen to Establish $200M Corporate Treasury Built Around Solana Cryptocurrency with BlockArrow Woburn, MA – August 7, 2025 – iSpecimen Inc. (NASDAQ: ISPC), a technology-enabled company modernizing the way human biospecimens are sourced for scientific research, today announced a major strategic initiative aimed at integrating digital assets into its business model. The company is l |
|
| August 5, 2025 |
Investor Relations Agreement by and between the Company and IR Agency LLC. Exhibit 10.3 ADDENDUM TO CONSULTING AGREEMENT Dated August 1, 2025 This Addendum to Consulting Agreement (this “Addendum”) is entered into for the purpose of amending the Consulting Agreement between IR Agency LLC (the “Consultant” or “IR Agency”) and iSpecimen Inc. (“you,” the “Client” or the “Company”) dated as of July 25, 2025, to provide for the purchase of additional Services by the Company u |
|
| August 5, 2025 |
Form of Registration Rights Agreement. Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (“Agreement”) is entered into as of July 31, 2025 by and among iSpecimen Inc., a Delaware corporation (the “Company”), and the purchasers from time to time party hereto (each, a “Purchaser” and collectively, the “Purchasers”). This Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date here |
|
| August 5, 2025 |
Form of Securities Purchase Agreement. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 31, 2025, between iSpecimen Inc., a Delaware corporation (the “Company”), and each of the purchasers identified on the signature pages hereto (each, including its successors and assigns, an “Purchaser” and collectively the “Purchasers”). RECITALS A. The Company and each Purchaser is |
|
| August 5, 2025 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 31, 2025 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of Incorporation) (Commission File Numbe |
|
| August 5, 2025 |
Exhibit 99.2 iSpecimen Inc. Announces Closing of Approximately $1.75 Million Private Placement Priced At-the-Market WOBURN, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) - iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it clo |
|
| August 5, 2025 |
Exhibit 99.1 iSpecimen Inc. Announces Pricing of Approximately $1.75 Million Private Placement Priced At-the-Market WOBURN, Mass., July 31, 2025 (GLOBE NEWSWIRE) - iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it ent |
|
| July 25, 2025 |
iSpecimen Inc. Announces Pricing of $4 Million Underwritten Offering Exhibit 99.1 iSpecimen Inc. Announces Pricing of $4 Million Underwritten Offering WOBURN, Mass., July 24, 2025 (GLOBE NEWSWIRE) - iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the pricing of an underwritten public offerin |
|
| July 25, 2025 |
PROSPECTUS Filed pursuant to Rule 424(b)(4) Registration No. 333-286958 1,482,644 SHARES OF COMMON STOCK PRE-FUNDED WARRANTS TO PURCHASE 4,231,639 SHARES OF COMMON STOCK 4,231,639 SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THE PRE-FUNDED WARRANTS iSpecimen Inc. We are offering on an underwritten basis 1,482,644 shares of our common stock, par value $0.0001 per share (the “Shares”) and 4, |
|
| July 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 23, 2025 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of Incorporation) (Commission File Numbe |
|
| July 25, 2025 |
iSpecimen Inc. Announces Closing of $4 Million Underwritten Offering Exhibit 99.2 iSpecimen Inc. Announces Closing of $4 Million Underwritten Offering WOBURN, Mass., July 25, 2025 (GLOBE NEWSWIRE) - iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the closing of its previously announced under |
|
| July 21, 2025 |
iSpecimen Inc. 8 Cabot Road, Suite 1800 Mt Woburn, WA 08101 iSpecimen Inc. 8 Cabot Road, Suite 1800 Mt Woburn, WA 08101 July 21, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549 Re: iSpecimen Inc. Request for Acceleration Registration Statement on Form S-1 File No. 333-286958 Ladies and Gentlemen: Pursuant to Rule 461 promulgated u |
|
| July 21, 2025 |
WestPark Capital, Inc. 1800 Century Park East, Suite 220 Los Angeles, CA 90067 WestPark Capital, Inc. 1800 Century Park East, Suite 220 Los Angeles, CA 90067 July 21, 2025 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: iSpecimen Inc. Registration Statement on Form S-1 File No. 333-286958 Acceleration Request Requested Date: Wednesday, July 23, 2025 Requested Time: 4:30 PM Eastern Time Ladies and |
|
| July 14, 2025 |
ISPECIMEN INC. 8 Cabot Road, Suite 1800 Woburn, MA 01801 ISPECIMEN INC. 8 Cabot Road, Suite 1800 Woburn, MA 01801 July 14, 2025 VIA EDGAR U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, DC. 20549 Attn: Nicholas O’Leary/Margaret Sawicki Re: iSpecimen Inc. Withdrawal of Acceleration Request for Registration Statement on Form S-1 File No. 333-286958 Ladies and Gentlemen: Reference is made to our letter, dated July 10, 2025, in which |
|
| July 14, 2025 |
WestPark Capital, Inc. 1800 Century Park East, Suite 220 Los Angeles, CA 90067 WestPark Capital, Inc. 1800 Century Park East, Suite 220 Los Angeles, CA 90067 July 14, 2025 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: iSpecimen Inc. Registration Statement on Form S-1 File No. 333-286958 WITHDRAWAL OF ACCELERATION REQUEST Ladies and Gentlemen: Reference is made to our letter, filed as correspond |
|
| July 10, 2025 |
Third Amended and Restated Bylaws of iSpecimen Inc. Exhibit 3.1 THIRD AMENDED AND RESTATED BY-LAWS OF ISPECIMEN INC. (as amended through July 9, 2025) ARTICLE I OFFICES Section 1.01 Registered Office. The registered office of iSpecimen Inc. (the “Corporation”) will be fixed in the Certificate of Incorporation of the Corporation, as may be amended from time to time (the “Certificate of Incorporation”). Section 1.02 Other Offices. The Corporation may |
|
| July 10, 2025 |
WestPark Capital, Inc. 1800 Century Park East, Suite 220 Los Angeles, CA 90067 WestPark Capital, Inc. 1800 Century Park East, Suite 220 Los Angeles, CA 90067 July 10, 2025 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: iSpecimen Inc. Registration Statement on Form S-1 File No. 333-286958 Acceleration Request Requested Date: Monday, July 14, 2025 Requested Time: 4:30 PM Eastern Time Ladies and Ge |
|
| July 10, 2025 |
iSpecimen Inc. 8 Cabot Road, Suite 1800 Mt Woburn, WA 08101 iSpecimen Inc. 8 Cabot Road, Suite 1800 Mt Woburn, WA 08101 July 10, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549 Re: iSpecimen Inc. Request for Acceleration Registration Statement on Form S-1 File No. 333-286958 Ladies and Gentlemen: Pursuant to Rule 461 promulgated u |
|
| July 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 9, 2025 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of Incorporation) (Commission File Number |
|
| July 8, 2025 |
As filed with the Securities and Exchange Commission on July 8, 2025. As filed with the Securities and Exchange Commission on July 8, 2025. Registration No. 333-286958 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1/A Amendment No. 4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 8731 27-0480143 (State or other jurisdiction of incorporation or org |
|
| June 27, 2025 |
As filed with the Securities and Exchange Commission on June 27, 2025. As filed with the Securities and Exchange Commission on June 27, 2025. Registration No. 333-286958 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1/A Amendment No. 3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 8731 27-0480143 (State or other jurisdiction of incorporation or or |
|
| June 27, 2025 |
June 27, 2025 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549 Attn: Mr. O’Leary / Ms. Sawicki Re: iSpecimen Inc. Amendment No. 2 to Registration Statement on Form S-1 Filed June 11, 2025 File No. 333-286958 Dear Mr. O’Leary and Ms. Sawicki: On behalf of iSpecimen Inc. (the “Company”), w |
|
| June 24, 2025 |
June 24, 2025 Robert Lim Chief Executive Officer iSpecimen Inc. 8 Cabot Road, Suite 1800 Woburn, MA 01801 Re: iSpecimen Inc. Amendment No. 2 to Registration Statement on Form S-1 Filed June 11, 2025 File No. 333-286958 Dear Robert Lim: We have reviewed your amended registration statement and have the following comment. Please respond to this letter by amending your registration statement and provi |
|
| June 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 18, 2025 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of Incorporation) (Commission File Numbe |
|
| June 11, 2025 |
Consulting Agreement by and between the Company and IR Agency LLC. Exhibit 10.45 CONSULTING AGREEMENT IR Agency LLC (the “Consultant” or “IR Agency”) is pleased to provide certain consulting services to iSpecimen Inc. (“you,” “Client” or “Company”) as more fully described in this agreement (the “Agreement”). This Agreement sets forth the terms and conditions pursuant to which Company engages Consultant to provide such services. 1. Consulting Services. (a) Commenc |
|
| June 11, 2025 |
As filed with the Securities and Exchange Commission on June 11, 2025. As filed with the Securities and Exchange Commission on June 11, 2025. Registration No. 333-286958 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1/A Amendment No. 2 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 8731 27-0480143 (State or other jurisdiction of incorporation or or |
|
| June 11, 2025 |
Exhibit 10.46 Definitive Service Agreement for the Development of the SalesStack This Definitive Software Purchase and Services Agreement (the “Agreement”) is made and entered into as of the Effective Date (defined in Section 1.3 below), by and between: iSpecimen Inc., a Delaware corporation with its principal place of business at 8 Cabot Road, Woburn MA 01801 (the “Purchaser”), AND Sales Stack So |
|
| June 11, 2025 |
June 11, 2025 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services Attn: Mr. O’Leary and Ms. Sawicki Re: iSpecimen Inc. Amendment No. 1 to Registration Statement on Form S-1 Filed May 23, 2025 File No. 333-286958 Dear Mr. O’Leary and Ms. Sawicki: On behalf of iSpecimen Inc. (the “Company”), we have set forth below response |
|
| June 9, 2025 |
June 9, 2025 Robert Lim Chief Executive Officer iSpecimen Inc. 8 Cabot Road, Suite 1800 Woburn, MA 01801 Re: iSpecimen Inc. Amendment No. 1 to Registration Statement on Form S-1 Filed May 23, 2025 File No. 333-286958 Dear Robert Lim: We have reviewed your amended registration statement and have the following comment. Please respond to this letter by amending your registration statement and providi |
|
| June 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 4, 2025 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of Incorporation) (Commission File Number |
|
| May 23, 2025 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) ISPECIMEN INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price(1)(3) Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common Stock, |
|
| May 23, 2025 |
As filed with the Securities and Exchange Commission on May 23, 2025. As filed with the Securities and Exchange Commission on May 23, 2025. Registration No. 333-286958 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1/A Amendment No. 1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 8731 27-0480143 (State or other jurisdiction of incorporation or org |
|
| May 23, 2025 |
Exhibit 10.46 Definitive Service Agreement for the Development of the SalesStack This Definitive Software Purchase and Services Agreement (the “Agreement”) is made and entered into as of the Effective Date (defined in Section 1.3 below), by and between: iSpecimen Inc., a Delaware corporation with its principal place of business at 8 Cabot Road, Woburn MA 01801 (the “Purchaser”), AND Sales Stack So |
|
| May 23, 2025 |
May 23, 2025 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549 Attn: Mr. O’Leary / Ms. Sawicki Re: iSpecimen Inc. Registration Statement on Form S-1 Submitted May 2, 2025 File No. 333-286958 Dear Mr. O’Leary and Ms. Sawicki: On behalf of iSpecimen Inc. (the “Company”), we have s |
|
| May 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-40501 iSpecimen Inc. ( |
|
| May 16, 2025 |
May 16, 2025 Robert Lim Chief Executive Officer iSpecimen Inc. 8 Cabot Road, Suite 1800 Woburn, MA 01801 Re: iSpecimen Inc. Registration Statement on Form S-1 Filed May 2, 2025 File No. 333-286958 Dear Robert Lim: We have conducted a limited review of your registration statement and have the following comments. Please respond to this letter by amending your registration statement and providing the |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2025 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Perio |
|
| May 2, 2025 |
Form of Underwriting Agreement between the Company and WestPark Capital, Inc. Exhibit 1.1 ISPECIMEN INC. UNDERWRITING AGREEMENT [*], 2025 WestPark Capital, Inc. 1800 Century Park East, Suite 220 Los Angeles, CA 90067 As Representative of the Several underwriters, if any, named in Schedule I hereto Ladies and Gentlemen: The undersigned, ISPECIMEN INC., a corporation formed under the laws of the State of Delaware (the “Company”), hereby confirms its agreement (this “Agreement |
|
| May 2, 2025 |
As filed with the Securities and Exchange Commission on May 2, 2025. As filed with the Securities and Exchange Commission on May 2, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 8731 27-0480143 (State or other jurisdiction of incorporation or organization) (Primary Stand |
|
| May 2, 2025 |
Exhibit 10.46 BETWEEN: iSpecimen Inc., a Delaware corporation, with its principal place of business at 8 Cabot Road, Woburn MA 01801 (the “Purchaser”) AND: Sales Stack Solutions Corp., a British Columbia Company, with a registered address at 25th Floor – 700 West Georgia Street, Vancouver B.C. V7Y 1K8 (the “Vendor”) WHEREAS: 1. The Purchaser has recently experienced technological challenges associ |
|
| May 2, 2025 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) ISPECIMEN INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price(1)(3) Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common Stock, |
|
| May 2, 2025 |
Form of Consulting Agreement by and between the Company and IR Agency LLC. Exhibit 10.45 CONSULTING AGREEMENT IR Agency LLC (the “Consultant” or “IR Agency”) is pleased to provide certain consulting services to iSpecimen Inc (“you,” “Client” or “Company”) as more fully described in this agreement (the “Agreement”). This Agreement sets forth the terms and conditions pursuant to which Company engages Consultant to provide such services. 1. Consulting Services. (a) Commenci |
|
| May 2, 2025 |
Form of Pre-Funded Warrant for Investors in this Offering. Exhibit 4.5 PRE-FUNDED COMMON STOCK PURCHASE WARRANT ISPECIMEN INC. Warrant Shares: Issue Date: , 2025 Initial Exercise Date: , 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after th |
|
| April 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40501 iSpecimen Inc. (Exact nam |
|
| March 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-K ☐ Transition Report o |
|
| March 11, 2025 |
Letter from Wolf & Company, P.C., dated March 11, 2025. Exhibit 16.1 March 11, 2025 Securities and Exchange Commission Washington, DC 20549 Commissioners: We have read iSpecimen Inc.’s statements included under Item 4.01 of its Form 8-K filed on March 11, 2025 and we agree with such statements concerning our firm. Boston, Massachusetts |
|
| March 11, 2025 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 7, 2025 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of Incorporation) (Commission File Numbe |
|
| February 28, 2025 |
Employment Agreement between iSpecimen Inc. and Katharyn Field, dated February 28, 2025 Exhibit 10.1 February 28th, 2025 Katharyn Field 22210 Woodset Lane Boca Raton, FL 33428 Dear Katie: I am pleased to confirm our offer to you of the position of President with iSpecimen Inc. (the “Company"), effective as of February 19, 2025 (your “Employment Date”). The purpose of this letter is to generally describe your employment with the Company and your agreement with the terms thereof. Job R |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 19, 2025 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of Incorporation |
|
| February 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 19, 2025 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of Incorporation) (Commission File N |
|
| January 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 16, 2025 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of Incorporation) (Commission File Nu |
|
| January 16, 2025 |
iSpecimen Secures Suppliers for COVID-style hMPV Outbreak Exhibit 99.1 iSpecimen Secures Suppliers for COVID-style hMPV Outbreak WOBURN, Mass., Jan. 16, 2025 (Newsfile Corp.) - iSpecimen Inc. (NASDAQ: ISPC), a leading online marketplace for human biospecimens, has secured suppliers for the flu-like human metapneumovirus (hMPV). The virus has been causing hospitals in China to become overrun, raising the potential for another COVID-style pandemic. iSpecim |
|
| December 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 27, 2024 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of Incorporation) (Commission File N |
|
| December 20, 2024 |
iSpecimen will serve as a Preferred Provider of Cancer Biospecimens Exhibit 99.1 iSpecimen will serve as a Preferred Provider of Cancer Biospecimens Woburn, MA, Dec. 20, 2024 (GLOBE NEWSWIRE) - iSpecimen Inc. (Nasdaq: ISPC), a leading online marketplace for human biospecimens, today announced its strategic initiatives for 2025, expanding services to procure high demand cancer biospecimens, enhancing its ability to support groundbreaking cancer research worldwide. |
|
| December 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 13, 2024 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of Incorporation) (Commission File N |
|
| December 20, 2024 |
Exhibit 10.1 YUYING LIANG PROFESSIONAL CORP. Vancouver, British Columbia Canada Telephone +1 778 318 7278 Private and Confidential December 13, 2024 Ms. Katharyn Field Director iSpecimen Inc. 8 Cabot Road, Suite 1800 Woburn, MA 01801 United States Dear Board of Directors: We appreciate the opportunity to provide accounting services to iSpecimen Inc. the (“Company”) in connection with the bookkeepi |
|
| December 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 13, 2024 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of Incorporation) (Commission File N |
|
| December 13, 2024 |
iSpecimen Reports Positive Results on Next Day Quote Program for Researchers and Providers Exhibit 99.1 iSpecimen Reports Positive Results on Next Day Quote Program for Researchers and Providers WOBURN, Mass., December 13, 2024 — iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today positive results attributed to its N |
|
| December 12, 2024 |
Exhibit 10.1 INDEPENDENT CONTRACTOR AGREEMENT This Independent Contractor Agreement (the “Agreement”) is made and entered into as of this December 9, 2024, by and between iSpecimen Inc., a Delaware corporation, and Robert Bradley Lim (the “Contractor”) through his personal corporation, 1513932 B.C. Ltd., a company incorporated under the laws of the Province of British Columbia, Canada. 1. Engageme |
|
| December 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 9, 2024 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of Incorporation) (Commission File Nu |
|
| December 12, 2024 |
iSpecimen Appoints Robert Lim as CEO and Director Exhibit 99.1 iSpecimen Appoints Robert Lim as CEO and Director WOBURN, Mass., December 12, 2024 — iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today that it has appointed Robert Lim as CEO and director. Mr. Lim is the principa |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 7, 2024 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of Incorporation) (Commission File Nu |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001- |
|
| October 31, 2024 |
TABLE OF CONTENTS Filed pursuant to Rule 424(b)(4) Registration No. 333-282736 PROSPECTUS 132,814 SHARES OF COMMON STOCK PRE-FUNDED WARRANTS TO PURCHASE 1,533,852 SHARES OF COMMON STOCK 1,533,852 SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THE PRE-FUNDED WARRANTS iSpecimen Inc. We are offering on a best-efforts basis 132,814 shares of our common stock, par value $0.0001 per share |
|
| October 31, 2024 |
Exhibit 10.3 CONSULTING AGREEMENT IR Agency LLC (the “Consultant” or “IR Agency”) is pleased to provide certain consulting services to iSpecimen Inc. (“you,” the “Client” or the “Company”) as more fully described in this agreement (the “Agreement”). This Agreement sets forth the terms and conditions pursuant to which the Company engages the Consultant to provide such services. 1. Consulting Servic |
|
| October 31, 2024 |
Exhibit 10.1 WestPark Capital, Inc. 1800 Century Park East, Suite 220 Los Angeles, CA 90067 October 29, 2024 iSpecimen Inc. 8 Cabot Road Woburn, MA 01801 Attention: Tracy Curley Dear Ms. Curley: Subject to the terms and conditions of this letter agreement (the “Agreement”), between WestPark Capital, Inc., as lead placement agent (“Placement Agent”), and iSpecimen Inc., a company organized under th |
|
| October 31, 2024 |
Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 29, 2024, between iSpecimen Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set fo |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 29, 2024 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of Incorporation) (Commission File Nu |
|
| October 31, 2024 |
Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT ISPECIMEN INC. Warrant Shares: Initial Exercise Date: , 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (“Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Ini |
|
| October 31, 2024 |
Exhibit 99.1 iSpecimen Inc. Announces Pricing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants WOBURN, Mass., October 29, 2024 – iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the pricing of its public |
|
| October 31, 2024 |
Exhibit 99.2 iSpecimen Inc. Announces Closing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants WOBURN, Mass., October 31, 2024 – iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the closing of its previo |
|
| October 28, 2024 |
iSpecimen Inc. 8 Cabot Road, Suite 1800 Mt Woburn, WA 08101 iSpecimen Inc. 8 Cabot Road, Suite 1800 Mt Woburn, WA 08101 October 28, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549 Re: iSpecimen Inc. Request for Acceleration Registration Statement on Form S-1 File No. 333-282736 Ladies and Gentlemen: Pursuant to Rule 461 promulgate |
|
| October 28, 2024 |
WestPark Capital, Inc. 1800 Century Park East, Suite 220 Los Angeles, CA 90067 WestPark Capital, Inc. 1800 Century Park East, Suite 220 Los Angeles, CA 90067 October 28, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: iSpecimen Inc. Registration Statement on Form S-1 File No. 333-282736 REQUEST FOR ACCELERATION OF EFFECTIVENESS Requested Date: Tuesday, October 29, 2024 Requested Ti |
|
| October 24, 2024 |
October 24, 2024 Tracy Curley Chief Executive Officer iSpecimen Inc. 8 Cabot Road, Suite 1800 Woburn, MA 01801 Re: iSpecimen Inc. Registration Statement on Form S-1 Filed October 18, 2024 File No. 333-282736 Dear Tracy Curley: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We re |
|
| October 18, 2024 |
Form of Securities Purchase Agreement for this offering. Exhibit 10.46 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2024, between iSpecimen Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set forth in th |
|
| October 18, 2024 |
Form of Consulting Agreement by and between the Company and IR Agency LLC. Exhibit 10.47 CONSULTING AGREEMENT IR Agency LLC (the “Consultant” or “IR Agency”) is pleased to provide certain consulting services to Ispecimen inc (“you,” the “Client” or the “Company”) as more fully described in this agreement (the “Agreement”). This Agreement sets forth the terms and conditions pursuant to which the Company engages the Consultant to provide such services. 1. Consulting Servic |
|
| October 18, 2024 |
Form of Pre-Funded Warrant for Investors in this Offering. Exhibit 4.4 PRE-FUNDED COMMON STOCK PURCHASE WARRANT ISPECIMEN INC. Warrant Shares: Initial Exercise Date: , 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (“Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Ini |
|
| October 18, 2024 |
Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) iSpecimen Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1)(2) Fee Rate Amount of Registration Fee Fees to Be Paid Equity Co |
|
| October 18, 2024 |
Form of Placement Agency Agreement between the Company and WestPark Capital, Inc. Exhibit 1.1 WestPark Capital, Inc. 1800 Century Park East, Suite 220 Los Angeles, CA 90067 [ ] [ ], 2024 iSpecimen, Inc. 8 Cabot Road Woburn, MA 01801 Attention: Tracy Curley Dear Ms. Curley: Subject to the terms and conditions of this letter agreement (the “Agreement”), between WestPark Capital, Inc., as lead placement agent (“Placement Agent”), and iSpecimen, Inc., a company organized under the |
|
| October 18, 2024 |
As filed with the Securities and Exchange Commission on October 18, 2024. TABLE OF CONTENTS As filed with the Securities and Exchange Commission on October 18, 2024. |
|
| October 2, 2024 |
Regulation FD Disclosure, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 25, 2024 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of Incorporation) (Commission File Numbe |
|
| September 25, 2024 |
Exhibit 4.1 THIS SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAI |
|
| September 25, 2024 |
Exhibit 10.1 NOTE PURCHASE AGREEMENT This Note Purchase Agreement (this “Agreement”) is dated as of September 18, 2024 between iSpecimen Inc., a Delaware corporation (the “Company”), and the purchaser identified on the signature page (including its successors and assigns, the “Investor”. WHEREAS, the Investor wishes to purchase from the Company, and the Company wishes to issue and sell to the Inve |
|
| September 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 19, 2024 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of Incorporation) (Commission File |
|
| September 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 11, 2024 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of incorporation) (Commission File |
|
| September 11, 2024 |
iSpecimen Announces 1-for-20 Reverse Stock Split Exhibit 99.1 iSpecimen Announces 1-for-20 Reverse Stock Split WOBURN, Mass., September 11, 2024 – iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today that it will effect a reverse stock split of its issued and outstanding share |
|
| September 11, 2024 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF iSPECIMEN INC. A DELAWARE CORPORATION PURSUANT TO SECTION 242 OF THE GENERAL CORPORATION LAW OF THE STATE OF DELAWARE iSpecimen Inc., a corporation duly organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify that: First: That the na |
|
| August 6, 2024 |
Exhibit 99.1 iSpecimen Reports Second Quarter 2024 Results Revenue increased 76% year-over-year to approximately $2.86 million Brielan Smiechowski Named SVP of Sales and Business Development LEXINGTON, Mass., August 6, 2024 – iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 6, 2024 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-40501 |
|
| August 6, 2024 |
Exhibit 99.2 August 2024 Investor Presentation Nasdaq: ISPC The Online Marketplace for Human Biospecimens Transforming Biospecimen Procurement This presentation may contain forward - looking statements within the meaning of Section 27 A of the Securities Act of 1933 , as amended, and Section 21 E of the Securities Exchange Act of 1934 , as amended . Such forward - looking statements are characteri |
|
| July 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 17, 2024 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| July 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 5, 2024 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of incorporation) (Commission File Number |
|
| July 3, 2024 |
Exhibit 10.2 450 Bedford Street | Lexington, MA 02420 | 781-301-6700 June 28, 2024 TO: BEDFORD STREET LLC: NOTICE OF LEASE TERMINATION This Notice of Lease Termination (the “Notice”) is in reference to the Seventh Amendment to the Lease Agreement (“Seventh Amendment”) dated September 27, 2023, by and between iSpecimen Inc. (“Tenant”) and Bedford Street LLC (“Landlord”). Date of Notice: June 28, 20 |
|
| July 3, 2024 |
Exhibit 10.1 CUMMINGS PROPERTIES, LLC COMMERCIAL LEASE Cummings Properties, LLC ("LESSOR") hereby leases to iSpecimen Inc. (a DE corp.), 450 Bedford Street, Suite 1010, Lexington, MA 02420 ("LESSEE"), the following premises, approximately 2,273 square feet (including 13% common area) at 8 Cabot Road, Suite 1800, Woburn, MA 01801 (“premises"), for an initial term of five years and two months commen |
|
| July 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 28, 2024 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| June 10, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule |
|
| June 10, 2024 |
Transforming Biospecimen Procurement An online marketplace for human biospecimens 2023 Annual Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 28, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION (Amendment No. 1) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as |
|
| May 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 16, 2024 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 7, 2024 |
Exhibit 99.2 May 2024 Investor Presentation Nasdaq: ISPC The Online Marketplace for Human Biospecimens Transforming Biospecimen Procurement This presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by futur |
|
| May 7, 2024 |
iSpecimen Reports First Quarter 2024 Results Exhibit 99.1 iSpecimen Reports First Quarter 2024 Results LEXINGTON, Mass., May 7, 2024 – iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today reported its financial and operating results for the three-month period ended March 31, 2024. “ |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-4050 |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 7, 2024 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| April 11, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 9, 2024 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| March 28, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 21, 2024 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| March 14, 2024 |
iSpecimen Reports Full Year 2023 Results Exhibit 99.1 iSpecimen Reports Full Year 2023 Results LEXINGTON, Mass., March 14 2024 – iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today reported its financial and operating results for the twelve-month period ended December 31, 2023. |
|
| March 14, 2024 |
Exhibit 99.2 March 2024 Investor Presentation Nasdaq: ISPC The Online Marketplace for Human Biospecimens Transforming Biospecimen Procurement This presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by fut |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 14, 2024 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| March 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number: 001-40501 iSpecime |
|
| March 13, 2024 |
iSpecimen Inc. Executive Compensation Clawback Policy (Adopted on October 27, 2023). Exhibit 97.1 ISPECIMEN INC. EXECUTIVE COMPENSATION CLAWBACK POLICY Adopted as of October 27, 2023 The Board of Directors (the “Board”) of iSpecimen Inc. (the “Company”) has adopted the following executive compensation clawback policy (this “Policy”). This Policy shall supplement any other clawback or compensation recovery policy or policies adopted by the Company or included in any agreement betwe |
|
| March 5, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 5, 2024 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of Incorporation) (Commission File Numbe |
|
| March 5, 2024 |
iSpecimen Inc. Up to $1,500,000 of Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration Statement 333-265976 PROSPECTUS SUPPLEMENT (To Prospectus dated July 12, 2022) iSpecimen Inc. |
|
| March 5, 2024 |
At the Market Offering Agreement, dated March 5, 2024, between the Company and Rodman & Renshaw LLC Exhibit 10.1 AT THE MARKET OFFERING AGREEMENT March 5, 2024 Rodman & Renshaw LLC 600 Lexington Avenue, 32nd Floor New York, NY 10022 Ladies and Gentlemen: iSpecimen Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with Rodman & Renshaw LLC (the “Manager”) as follows: 1. Definitions. The terms that follow, when used in t |
|
| February 15, 2024 |
Exhibit 10.1 WARRANT REPURCHASE AND TERMINATION AGREEMENT This WARRANT REPURCHASE AND TERMINATION AGREEMENT (this “Agreement”), dated and effective as of , 2024 (the “Effective Date”), is entered into by and between (“Warrant Holder”), and iSpecimen Inc., a Delaware corporation (the “Company”). The Warrant Holder and the Company are sometimes each referred to herein as a “Party” and collectively a |
|
| February 15, 2024 |
Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 13, 2024 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of Incorporation) (Commission File N |
|
| February 13, 2024 |
ISPC / iSpecimen Inc. / OBF Investments, LLC Passive Investment SC 13G/A 1 tm61.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* iSpecimen Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45032V108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| December 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 15, 2023 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of Incorporation) (Commission File N |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 2, 2023 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 2, 2023 |
Exhibit 99.2 November 2023 Investor Presentation Nasdaq: ISPC The Online Marketplace for Human Biospecimens Transforming Biospecimen Procurement This presentation may contain forward - looking statements within the meaning of Section 27 A of the Securities Act of 1933 , as amended, and Section 21 E of the Securities Exchange Act of 1934 , as amended . Such forward - looking statements are characte |
|
| November 2, 2023 |
Exhibit 99.1 iSpecimen Reports Third Quarter 2023 Financial and Operating Results Sequential Quarterly Revenue Growth of 75% Driven by Enhanced Operational Efficiencies of iSpecimen Marketplace and Rollout of New Business Initiatives LEXINGTON, Mass., November 2, 2023 – iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring bio |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001- |
|
| October 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 23, 2023 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| October 23, 2023 |
Exhibit 99.1 iSpecimen Preannounces Third Quarter 2023 Revenue Increase of 60-70% Sequentially Management to Host Third Quarter 2023 Conference Call on Thursday, November 2, 2023 LEXINGTON, Mass., October 23, 2023 – iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of health |
|
| October 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 9, 2023 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of incorporation) (Commission File Num |
|
| September 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 6, 2023 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of incorporation) (Commission File N |
|
| September 6, 2023 |
Exhibit 99.1 iSpecimen Announces Organizational Changes to Enhance Operational Efficiencies and Drive Profitability Company to Focus on Core Revenue Drivers, New Revenue Growth Opportunities from Recently Launched Sequencing Procurement Program and Expense Reductions LEXINGTON, Mass., September 6, 2023 – iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace tha |
|
| August 2, 2023 |
iSpecimen Reports Second Quarter 2023 Financial and Operating Results Exhibit 99.1 iSpecimen Reports Second Quarter 2023 Financial and Operating Results LEXINGTON, Mass., August 2, 2023 – iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today reported its financial and operating results for the three and six |
|
| August 2, 2023 |
Exhibit 99.2 August 2023 Investor Presentation Nasdaq: ISPC The Online Marketplace for Human Biospecimens Transforming Biospecimen Procurement This presentation may contain forward - looking statements within the meaning of Section 27 A of the Securities Act of 1933 , as amended, and Section 21 E of the Securities Exchange Act of 1934 , as amended . Such forward - looking statements are characteri |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 2, 2023 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-40501 |
|
| July 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 7, 2023 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of Incorporation) (Commission File Number |
|
| May 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 24, 2023 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of Incorporation) (Commission File Number |
|
| May 25, 2023 |
Amendment No. 1 to iSpecimen Inc. Second Amended and Restated 2021 Stock Incentive Plan AMENDMENT NO. 1 TO iSPECIMEN INC. AMENDED AND RESTATED 2021 STOCK INCENTIVE PLAN WHEREAS, iSpecimen Inc. (the “Company”) has adopted the 2021 Stock Incentive Plan, effective June 16, 2021, which was amended and restated twice since adoption and the Second Amended and Restated 2021 Stock Incentive Plan was approved by the of holders of the Company’s common stock (“Common Stock”), $0.0001 par value |
|
| May 4, 2023 |
iSpecimen Reports First Quarter 2023 Results - Quarterly Revenue Increased 17% Year-Over-Year - Exhibit 99.1 iSpecimen Reports First Quarter 2023 Results - Quarterly Revenue Increased 17% Year-Over-Year - LEXINGTON, MA, May 4, 2023 – iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today reported its financial and operating results fo |
|
| May 4, 2023 |
Exhibit 99.2 May 2023 Investor Presentation Transforming Biospecimen Procurement An online marketplace for human biospecimens This presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or condition |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-4050 |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 4, 2023 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| April 17, 2023 |
ISPC / iSpecimen Inc / Ross Andrew L. - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* iSpecimen Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 45032V108 (CUSIP Number) Andrew L. Ross c/o iSpecimen Inc. 450 Bedford Street Lexington, MA 02420 (781) 301-6700 (Name, Address and Telephone Number of Person A |
|
| April 10, 2023 |
DEFA14A 1 tm232091d5defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (a |
|
| April 10, 2023 |
Transforming Biospecimen Procurement An online marketplace for human biospecimens 2022 Annual Report 450 Bedford Street | Lexington, MA 02420 | 781-301-6700 Dear Fellow Stockholders, It is an exciting time to be associated with iSpecimen. |
|
| April 10, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule |
|
| March 31, 2023 |
Exhibit 10.2 SECOND AMENDMENT TO first amended and restated executive employment agreement This is a contractual amendment to the First Amended and Restated Executive Employment Agreement between iSpecimen, Inc. (the “Company”) and TRACY WILSON CURLEY (the “Executive”), executed on October 24th, 2022, as previously amended by the First Amendment to the First Amended and Restated Executive Employme |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 31, 2023 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| March 31, 2023 |
Exhibit 10.1 first AMENDMENT TO first amended and restated executive employment agreement This is a contractual amendment to the First Amended and Restated Executive Employment Agreement between iSpecimen, Inc. (the “Company”) and TRACY WILSON CURLEY (the “Executive”), executed on October 24th, 2022 (the “Agreement”). WHEREAS, the Company and Executive do now mutually desire to amend the Agreement |
|
| March 31, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period FromTo Commission file number: 001-40501 iSpeci |
|
| March 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period FromTo Commission file number: 001-40501 iSpecimen Inc. (Exact name |
|
| March 14, 2023 |
Exhibit 99.1 iSpecimen Reports Full Year 2022 Results - Reported Record Quarterly Revenue of $3.2 Million, Up 28% Year-Over-Year - LEXINGTON, MA, March 14, 2023 – iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare specimen providers, today reported its financia |
|
| March 14, 2023 |
Exhibit 99.2 CONNECT. INNOVATE. March 2023 Investor Presentation TRANSFORMING BIOSPECIMEN PROCUREMENT An online marketplace for human biospecimens This presentation may contain forward - looking statements within the meaning of Section 27 A of the Securities Act of 1933 , as amended, and Section 21 E of the Securities Exchange Act of 1934 , as amended . Such forward - looking statements are charac |
|
| March 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 14, 2023 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| February 13, 2023 |
ISPC / iSpecimen Inc. / OBF Investments, LLC Passive Investment SC 13G/A 1 tm20.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* iSpecimen Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45032V108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| January 12, 2023 |
ISPC / iSpecimen Inc. / Empery Asset Management, LP - ISPECIMEN INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* iSpecimen Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 45032V108 (CUSIP Number) December 31, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this Sch |
|
| January 10, 2023 |
Exhibit 99.1 iSpecimen Names Tracy Curley as Chief Executive Officer - Previously Appointed Interim CEO in September 2022 - LEXINGTON, Mass. – January 10, 2023 – iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare specimen providers, announced today that its Boa |
|
| January 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 9, 2023 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of incorporation) (Commission File Num |
|
| December 30, 2022 |
Prospectus Supplement No. 1 to Reoffer Prospectus iSpecimen Inc. Filed Pursuant to Rule 424(b)(3) Registration No. 333-261701 Prospectus Supplement No. 1 to Reoffer Prospectus of iSpecimen Inc. Up to 734,152 shares of Common Stock under the iSpecimen Inc. 2010 Stock Incentive Plan, the iSpecimen Inc. 2013 Stock Incentive Plan and the iSpecimen Inc. Second Amended and Restated 2021 Stock Incentive Plan. This Prospectus Supplement, dated December 30, 2022 (this ? |
|
| December 27, 2022 |
ISPC / iSpecimen Inc. / Wolf James G. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT §240.13d-2 (Amendment No. 1) iSPECIMEN INC. (Name of Issuer) Common Stock $.0001 Par Value (Title of Class of Securities) 45032V108 (CUSIP Number) December 23, 2022 (Date of |
|
| November 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 28, 2022 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of incorporation) (Commission File N |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001- |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 8, 2022 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 8, 2022 |
Investor Presentation, dated November 2022. Exhibit 99.2 CONNECT. INNOVATE. TRANSFORMING PROCUREMENT BIOSPECIMEN An online marketplace for human biospecimens November 2022 Investor Presentation Forward-Looking Statements This presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking |
|
| November 8, 2022 |
Exhibit 99.1 iSpecimen Reports Third Quarter 2022 Financial and Operating Results - Reported Revenue of $2.6 Million, Comprised Of A Record 88% Non-COVID Revenue - LEXINGTON, MA, November 8, 2022 ? iSpecimen Inc. (Nasdaq: ISPC) (?iSpecimen? or the ?Company?), an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare specimen pro |
|
| October 28, 2022 |
Exhibit 10.1 iSpecimen, Inc. FIRST AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the ?Agreement?) made as of this 24 day of October, 2022, between Tracy Wilson Curley (the ?Executive?), and iSpecimen, Inc., a Delaware corporation located at 450 Bedford St, Lexington, MA 02420 (the ?Company?). Whereas, the Board of Directors of the Com |
|
| October 28, 2022 |
Exhibit 10.2 iSpecimen, Inc. FIRST RESTATED NONCOMPETITION, NONSOLICITATION, NONDISCLOSURE AND INVENTIONS AGREEMENT The undersigned, TRACY WILSON CURLEY, in consideration for and as a condition of employment as a senior executive officer (the ?Executive?) of iSpecimen, Inc. (the ?Company?), or for receiving stock or options, or any other form of compensation, salary, bonus, benefit or fringe benef |
|
| October 28, 2022 |
Exhibit 10.4 iSpecimen, Inc. FIRST RESTATED NONCOMPETITION, NONSOLICITATION, NONDISCLOSURE AND INVENTIONS AGREEMENT The undersigned, BENJAMIN BIELAK, in consideration for and as a condition of employment as a senior executive officer (the ?Executive?) of iSpecimen, Inc. (the ?Company?), or for receiving stock or options, or any other form of compensation, salary, bonus, benefit or fringe benefits |
|
| October 28, 2022 |
Exhibit 10.5 October 24, 2022 Christopher Ianelli, MD, Ph.D. Re:??????Separation Agreement Dear Chris, This letter sets forth the substance of the separation agreement (the ?Agreement?) which ISPECIMEN INC. (the ?Company?) is offering to you to aid in your employment transition. Separation. Your last day of work with the Company and your employment termination date will be October 24, 2022 (the ?S |
|
| October 28, 2022 |
Exhibit 10.3 iSpecimen, Inc. FIRST AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the ?Agreement?) made as of this 24th day of October, 2022, between Benjamin Bielak (the ?Executive?), and iSpecimen, Inc., a Delaware corporation located at 450 Bedford St, Lexington, MA 02420 (the ?Company?). Whereas, the Board of Directors of the Compa |
|
| October 28, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 24, 2022 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| October 28, 2022 |
Exhibit 10.6 October 24, 2022 Jill Mullan Re:??????Separation Agreement Dear Jill, This letter sets forth the substance of the separation agreement (the ?Agreement?) which ISPECIMEN INC. (the ?Company?) is offering to you to aid in your employment transition. Separation. Your last day of work with the Company and your employment termination date will be October 24, 2022 (the ?Separation Date?). Th |
|
| September 28, 2022 |
ISPC / iSpecimen Inc. / Wolf James G. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT §240.13d-2 (Amendment No. ) iSPECIMEN INC. (Name of Issuer) Common Stock $.0001 Par Value (Title of Class of Securities) 45032V108 (CUSIP Number) September 23, 2022 (Date of Ev |
|
| September 22, 2022 |
EX-99.1 2 tm2226424d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 iSpecimen Names Chief Financial Officer, Tracy Curley, Interim CEO - Current President and CEO, Christopher Ianelli, to Leave Company - LEXINGTON, Mass., September 22, 2022 – iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists in need of biospecimens for medical research with a |
|
| September 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 19, 2022 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 001-40501 27-0480143 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 5, 2022 |
iSpecimen Inc. 2,598,473 Shares of Common Stock TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(3)? ?Registration No. 333-266384? PROSPECTUS iSpecimen Inc. 2,598,473 Shares of Common Stock This prospectus relates to the resale by the selling stockholders named herein, or their respective transferees, pledgees, donees or other successors-in-interest, from time to time, of up to an aggregate of 2,598,473 shares of common stock, par value $0.0001 |
|
| August 4, 2022 |
Exhibit 99.1 iSpecimen Reports Second Quarter 2022 Financial and Operating Results - Enhanced iSpecimen Marketplace Platform? with Data Integration Capabilities to Simplify the Ingestion and Maintenance of Biospecimen Inventories for Providers - LEXINGTON, MA, August 4, 2022 ? iSpecimen Inc. (Nasdaq: ISPC) (?iSpecimen? or the ?Company?), an online global marketplace that connects scientists in nee |
